Galectin Therapeutics
GALT
98 hedge funds and large institutions have $72.2M invested in Galectin Therapeutics in 2026 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 23 reducing their positions, and 20 closing their positions.
179% more call options, than puts
Call options by funds: $5.31M | Put options by funds: $1.9M
86% more capital invested
Capital invested by funds: $38.8M → $72.2M (+$33.4M)
39% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 23
2.12% more ownership
Funds ownership: 21.62% → 23.74% (+2.1%)
0% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 20
1% less funds holding
Funds holding: 99 → 98 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.67M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.8M |
| 3 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$850K |
| 4 |
State Street
Boston,
Massachusetts
|
+$802K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$664K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.98M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.01M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$981K |
| 4 |
Jane Street
New York
|
-$505K |
| 5 |
6CM
683 Capital Management
New York
|
-$453K |
GALT Hedge Fund Activity: Q2 2026 in Review
98 of the 8,286 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2026, worth a combined $72.2M — up 86% from $38.8M a quarter earlier.
Fund positioning in GALT was balanced in Q2 2026: 20 funds opened new positions, 20 closed out, 32 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $5.67M. The largest seller was Millennium Management, cutting an estimated $1.98M.
- 98 institutional investors held Galectin Therapeutics (GALT) as of Q2 2026, down from 99 in Q1 2026.
- Funds reported $72.2M of Galectin Therapeutics stock for Q2 2026, up 86% quarter-over-quarter.
- 20 funds opened new Galectin Therapeutics positions in Q2 2026 and 20 closed out, a net change of 0 holders.
- The largest Galectin Therapeutics buyer in Q2 2026 was BlackRock, an estimated $5.67M added.
- The largest Galectin Therapeutics seller in Q2 2026 was Millennium Management, an estimated $1.98M sold.
Based on aggregated 13F filings for Q2 2026.